Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00667797 · ClinicalTrials.gov registry record · Phase 4

Costs & Outcomes of Hospitalization/Treatment With Levalbuterol & Albuterol in Asthma or Chronic Obstructive Pulmonary Disease (COPD) Subjects

A Phase 4 study, sponsored by Sumitomo Pharma America.

Completed
Registry status
Phase 4
Development phase
486
Enrollment target

NCT00667797 is a Phase 4 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 486 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00667797, a Phase 4 study, has completed, sponsored by Sumitomo Pharma America.

COMPLETED
Registry status
Phase 4
Development phase
486 participants
Enrollment target

Study Summary

An analysis of the costs and outcomes associated with hospitalization and treatment of Levalbuterol versus Racemic Albuterol in subjects with Asthma and COPD.

Interventions

  • DRUG levalbuterol HCl
  • DRUG albuterol Sulfate

Trial Details

FieldValue
Enrollment Target 486 participants
Start Date 2003-03
Est. Completion 2005-05
Phase Phase 4

Sponsor

Sumitomo Pharma America

168 total trials

What the Registry Record Tells You About NCT00667797

The ClinicalTrials.gov registry entry for NCT00667797 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 486 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which levalbuterol HCl is the first listed.

NCT00667797 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00667797 about?

NCT00667797 is a clinical study titled "Costs & Outcomes of Hospitalization/Treatment With Levalbuterol & Albuterol in Asthma or Chronic Obstructive Pulmonary Disease (COPD) Subjects". An analysis of the costs and outcomes associated with hospitalization and treatment of Levalbuterol versus Racemic Albuterol in subjects with Asthma and COPD.

What is the current status of trial NCT00667797?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 486 participants. The study started on 2003-03. Estimated completion is 2005-05.

What interventions are being tested in trial NCT00667797?

The interventions under investigation include: levalbuterol HCl (DRUG), albuterol Sulfate (DRUG).

Who is sponsoring clinical trial NCT00667797?

This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.